Coagulation factor IXa and factor VIIIa complex (Intrinsic tenase complex) (Intrinsic tenase complex)

The intrinsic tenase complex is a pivotal enzymatic assembly in the secondary hemostasis pathway, consisting of the activated serine protease factor IX (FIXa) and its essential non-enzymatic cofactor, activated factor VIII (FVIIIa) (StatPearls, NBK482256). This complex assembles on the surface of activated platelets in a calcium-dependent manner to efficiently convert factor X into activated factor X (FXa), a step that is rate-limiting for the subsequent burst of thrombin generation (Journal of Thrombosis and Haemostasis, 10.1111/jth.12217). Deficiencies in the components of this complex lead to hemophilia; specifically, a lack of FVIII causes Hemophilia A, while a lack of FIX causes Hemophilia B (StatPearls, NBK482256). Because the complex is central to the amplification of the coagulation cascade, it is a major therapeutic target for treating bleeding disorders (NEJM, 10.1056/NEJMoa1703068). Innovative therapies like emicizumab are bispecific antibodies designed to mimic the function of FVIIIa by physically bridging FIXa and FX, thereby restoring the enzymatic activity of the tenase complex in Hemophilia A patients (FDA, Hemlibra Label). Conversely, pharmacological inhibition of this complex is a potential strategy for anticoagulation to prevent thrombosis (Journal of Thrombosis and Haemostasis, 10.1111/jth.12217).

Other names

Intrinsic tenase complexFIXa-FVIIIa complexFactor X-activating complexFactor IXa-Factor VIIIa complexTenase complex

Bispecific antibodies mimic the function of activated factor VIII by bridging activated factor IX and factor X, thereby facilitating the assembly of a functional tenase-like complex and the subsequent activation of factor X.